In pediatric patients, Kluyvera spp. has emerged as a cause of disease ranging from soft tissue infections to sepsis with multiorgan failure. Successful treatment options include third-generation cephalosporins, tetracycline, aminoglycosides, and fluoroquinolones, but resistance to first- and second-generation cephalosporins persists. Clinicians should be aware of the spectrum of disease and increasing clinical importance associated with this emerging pathogen.
From the Department of Pathology, University of South Alabama, Mobile, AL.
Accepted for publication February 26, 2008.
Address for correspondence: J. Elliot Carter, MD, Department of Pathology, University of South Alabama, 2451 Fillingim Street, Mobile, AL 36617. E-mail: firstname.lastname@example.org.